



The C-terminal domain of the antiamyloid chaperone DNAJB6 binds to amyloid- β peptide fibrils and inhibits secondary nucleation

Received for publication, March 21, 2023, and in revised form, September 13, 2023. Published, Papers in Press, October 4, 2023.

<https://doi.org/10.1016/j.jbc.2023.105317>

Nicklas Österlund^{1,*}, Rebecca Frankel², Andreas Carlsson², Dev Thacker², Maja Karlsson², Vanessa Matus², Astrid Gräslund¹, Cecilia Emanuelsson², and Sara Linse^{2,*}

From the ¹Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden; ²Division of Biochemistry and Structural Biology, Department of Chemistry, Lund University, Lund, Sweden

Reviewed by members of the JBC Editorial Board. Edited by Karen Fleming

The DNAJB6 chaperone inhibits fibril formation of aggregation-prone client peptides through interaction with aggregated and oligomeric forms of the amyloid peptides. Here, we studied the role of its C-terminal domain (CTD) using constructs comprising either the entire CTD or the first two or all four of the CTD β -strands grafted onto a scaffold protein. Each construct was expressed as WT and as a variant with alanines replacing five highly conserved and functionally important serine and threonine residues in the first β -strand. We investigated the stability, oligomerization, antiamyloid activity, and affinity for amyloid- β (A β 42) species using optical spectroscopy, native mass spectrometry, chemical crosslinking, and surface plasmon resonance technology. While DNAJB6 forms large and polydisperse oligomers, CTD was found to form only monomers, dimers, and tetramers of low affinity. Kinetic analyses showed a shift in inhibition mechanism. Whereas full-length DNAJB6 activity is dependent on the serine and threonine residues and efficiently inhibits primary and secondary nucleation, all CTD constructs inhibit secondary nucleation only, independently of the serine and threonine residues, although their dimerization and thermal stabilities are reduced by alanine substitution. While the full-length DNAJB6 inhibition of primary nucleation is related to its propensity to form coaggregates with A β , the CTD constructs instead bind to A β 42 fibrils, which affects the nucleation events at the fibril surface. The retardation of secondary nucleation by DNAJB6 can thus be ascribed to the first two β -strands of its CTD, whereas the inhibition of primary nucleation is dependent on the entire protein or regions outside the CTD.

DnaJ/Hsp40 proteins are important ATP-independent chaperones that bind to specific client proteins and deliver them to the Hsp70 machinery (1). The DnaJ family includes 45 different homologs in human, divided into three subfamilies (A, B, and C), of which the B subfamily has been shown to be

linked to suppression of protein aggregation (2). The B subfamily can be further divided into a classical (DNAJB1, and related) and a nonclassical (DNAJB6, DNAJB8, and related) cluster. DNAJB1-like chaperones participate in the eukaryotic protein disaggregation system that increases the rate of amyloid fibril dissociation (3, 4). DNAJB6 has been found to massively retard the formation of amyloid fibrils and to affect the equilibrium solubility of amyloid peptides (5, 6). Among the proteins for which amyloid formation is reported to be suppressed by DNAJB6 *in vivo* and *in vitro* are poly-Q peptides from Huntington's disease (7–10), α -synuclein from Parkinson's disease (11, 12), and amyloid- β (A β) peptides A β 40 (13) and A β 42 (5, 6) from Alzheimer's disease. The A β 42 peptide, the client studied in this current work, aggregates *via* a double nucleation mechanism (14). Primary nucleation of monomers in solution is a very slow event, whereas the energy barrier is significantly reduced for fibril-dependent secondary nucleation of monomers, leading to a much faster nucleation of amyloid (14, 15). Elongation of existing fibrils by monomer addition is associated with the lowest energy barrier (15). The effect of DNAJB6 on A β 42 aggregation is due to not only strong suppression of primary nucleation but also suppression of secondary nucleation (5). The presence of the chaperone also shifts the equilibrium toward higher solubility of A β 42 (6). A β aggregation is affected at remarkably low substoichiometric molar ratios of chaperone to client peptide, and the interaction is believed to be with oligomeric rather than monomeric or fibrillar forms of A β (5, 13). The exact mechanism and driving forces behind chaperone action and chaperone–client interactions, however, remain largely unknown.

DNAJB6 contains two globular domains, the J-domain (JD) and the C-terminal domain (CTD), connected by a relatively unstructured linker domain rich in serine (S), threonine (T), glycine (G), and phenylalanine (F) residues, as seen in an AlphaFold2 prediction (Fig. 1A). The JD is highly conserved, is found in all DnaJ proteins, and interacts with Hsp70 *via* a conserved HPD motif (16, 17). J protein CTDs have considerably more structural diversity but have been found to be important for binding of client proteins (16, 17) and is in DNAJB proteins known to be critical for their antiaggregation function *in vivo* (2). DNAJB6-like J-proteins have one CTD

* For correspondence: Nicklas Österlund, nicklas.osterlund@fu-berlin.de; Sara Linse, sara.linse@biochemistry.lu.se.

Present address for Nicklas Österlund: Institut für Chemie und Biochemie Organische Chemie, Freie Universität Berlin, Berlin 14195, Germany.

The DNAJB6 C-terminal domain inhibits secondary nucleation




Figure 1. Structural outline DNAJB6 and its C-terminal domain (CTD). A, structural model of DNAJB6b as predicted by AlphaFold2. The protein is colored according to sequence position from blue (N-terminal end) to red (C-terminal end). B, residues 132 to 242 in the AlphaFold2 model, including the linker and CTD with the S/T residues that have been found to be of importance for the anti-amyloid effect of full-length DNAJB6, highlighted as spheres in hot pink (5 residues in in β -strand 1) and pink (ten residues in the linker). C, previously published DNAJB6 dimer model as predicted by HADDOCK docking with two experimental restraints (18), in which two CTDs are positioned at the dimer interface. Lysine residues are shown as spheres, with lysines found to crosslink with A β 42 colored purple (18). D, peptide docking of A β 42 to DNAJB6 residues 132 to 242 in AlphaFold2, showing the three top ranked models overlaid. Left, colored according to chain, CTD in orange, A β 42 in cyan. Right, colored according to pLDDT score (red to blue). E, NMR structure of the independently folded CTD (Protein Data Bank code: 7JSQ (22)), which is studied here. Residues in β 1 are highlighted as sticks for the CTD construct and the S/T-A-substituted variant (CTD STA), which is also studied.

that consists of a single β -sheet. DNAJB6 and its closest homologs also contain a characteristic stretch of highly conserved S/T residues in and just N-terminal to β -strand 1 (β 1) of the CTD (Fig. 1B). Substitution of these S/T residues with alanines reduces the effects of DNAJB6 on both amyloid nucleation and A β solubility (6). A previously published dimer model of DNAJB6 suggests that the two β 1 strands in the CTDs are solvent accessible in the dimer and in an antiparallel arrangement at the monomer–monomer interface (18) (Fig. 1C). Crosslinking mass spectrometry (MS) detects lysine-specific chemical crosslinks between A β 42 and four lysine residues in the CTD (Fig. 1C, purple spheres) (18). No crosslinks are detected between A β 42 and the JD, whereas the unstructured linker in DNAJB6 does not contain any lysines and is thus unavailable for crosslinking (18). This indicates that the CTD may be important for chaperone–client interactions in DNAJB6. Peptide docking in AlphaFold2 does indeed suggest a complex where A β interacts preferentially with the S/T-rich β 1 in the CTD (Fig. 1D) (19).

DNAJB6 has a high tendency to form highly polydisperse oligomers, in contrast to DNAJB1 that functions as a dimer (20, 21). The polydispersity of DNAJB6 is seen as a broad elution in size-exclusion chromatography (SEC) and a lack of discrete bands on native electrophoresis gels (7). Electron microscopy reveals a loose oligomeric structure full of voids and only small interaction surfaces between the proteins in the oligomers (18). The self-assembly of DNAJB6 into oligomers is partly dependent on the CTD and partly on the functionally important S/T-rich region in the unstructured linker domain,

as deletion of 20 or 55 amino acid residues (Δ 132–183) before β 1 of CTD results in a reduction of oligomers and an increase in monomer concentration (6, 22). NMR data point toward an important role of the five S/T residues in β 1 for strand twisting, intermolecular strand–strand interactions, and chaperone self-affinity. The NMR data further imply that the T193A point mutation decreases the CTD dimerization/oligomerization propensity and affects the local dynamics of β 1 (23, 24). *In vivo*, the T193A mutation is associated with altered α -synuclein homeostasis and Parkinson’s disease (25), indicating a possible correlation between DNAJB6 oligomerization and chaperone activity.

This study was motivated by the potent inhibition by DNAJB6 of both primary and secondary nucleation of A β 42, the more aggregation-prone of the A β alloforms. We ask whether the effects of full-length DNAJB6 on A β 42 fibril formation kinetics and oligomer formation can be mimicked by the CTD, the putative client-binding domain. The CTD was earlier found to be an independent folding unit (22, 23) and is here studied *in vitro* in isolation and together with A β 42. *In vitro* studies offer tighter control over the composition of systems, and previous studies have found that the same mechanistic steps describe aggregation in buffer and cerebrospinal fluid (CSF) (26), and that inhibitors act on the same steps in both environments (27). One construct with the DNAJB6 WT sequence (residues 186–242 plus a starting Met), referred to as CTD, and one variant with five S/T to A substitutions in β 1 (S190A + S192A + T193A + S194A + T195A), referred to as CTD STA, are studied (Fig. 1E). This STA

variant was designed based on the previously observed decrease in anti-amyloid activity of full-length DNAJB6 with these substitutions (6) to study whether this effect is replicated by the isolated CTD. Shorter segments comprising $\beta 1$ – $\beta 2$ or $\beta 1$ – $\beta 4$ of CTD grafted onto S100G, referred to as S100G-CTD $\beta 1$ –2 and S100G-CTD $\beta 1$ –4 (Fig. S1), are studied to further pinpoint the interactions with A β 42. The effect of each construct on A β 42 aggregation is monitored using thioflavin T (ThT) fluorescence, the interaction with A β 42 fibrils using surface resonance technology, and the formation of small coaggregates with A β 42 by native MS. The stability toward thermal denaturation is studied using CD spectroscopy and native MS. The Ca²⁺-binding affinity and cooperativity for S100G-grafted constructs are studied using a competitive spectroscopic assay to monitor any perturbations of the host scaffold.

Results

The stability toward unfolding of the CTD

Far-UV CD spectroscopy reports on the average secondary structure content in a sample. CTD displays a far-UV CD spectrum typical of a β -sheet-rich protein in 20 mM sodium phosphate, pH 8.0, at 5 °C, with a minimum at 216 nm and a maximum at 198 nm (Fig. 2B, blue trace). CTD STA displays

an altered spectrum with less negative ellipticity at 216 nm and no peak at 205 nm (Fig. 2B, red trace). Both proteins seem to denature completely at high temperature with spectra typical of random coil observed at 95 °C (Fig. 2B, dashed lines). The thermal denaturation data indicate that the temperature at the denaturation midpoint (T_m) is 58 °C for CTD but only 39 °C for CTD STA (Fig. 2C). Neither protein refolds completely upon returning to 5 °C (Fig. S2), after which CTD STA is retained in a mostly unstructured state, whereas CTD is partially refolded to an intermediate state, with similar spectrum as the initial state of CTD STA.

The charge state distributions of ionized CTD and CTD STA were analyzed using electrospray MS. The proteins were ionized from 200 mM ammonium acetate, pH 6.8, at a source temperature of 25 °C. Electrospray MS was performed using very gentle ionization settings that are able to retain non-covalent interactions upon transfer to the gas phase (so-called “native” MS). CTD and CTD STA samples were mixed for native MS analysis, as the difference in mass between the constructs makes them easily separable in the m/z dimension. Analyzing both proteins in the same samples eliminate errors that could be due to variations in ionization efficiency between samples.

Both proteins are observed as mostly monomers after ionization in native MS (Fig. 2A), with narrow charge state




Figure 2. Structural characterization of C-terminal domain (CTD) constructs. A, native MS of an equimolar mixture of CTD and CTD STA as ionized from 200 mM ammonium acetate (pH 6.8). The charge state distribution is shifted toward higher charge states for CTD STA (red) compared with CTD (blue). The Rayleigh limit (z_R) is indicated, which is the maximum theoretical charge that a spherically folded CTD protein could acquire during electrospray ionization. Charge states higher than z_R likely correspond to partially unfolded structural states. B, far-UV CD spectra of CTD (blue) and CTD STA (red) at 5 °C (solid lines), at 95 °C (dashed lines) in 20 mM sodium phosphate, pH 8.0. C, thermal denaturation of CTD and CTD STA as monitored by the CD signal at 216 nm. D, dimer regime of the mass spectrum for the mixture of CTD and CTD STA, indicating the presence of both homodimers and heterodimers, with CTD having a higher dimerization propensity compared with CTD STA. An insert of the ion mobility drift times for the overlapping $n/z = 1/3, 2/6$ peak is shown. E, SDS-PAGE analysis of CTD and CTD STA with (+) and without (–) crosslinking prior to analysis. The uncropped gel is shown in Fig. S12A. The residues involved in the detected crosslinks are shown in the structural model of CTD; for further details, see Table 1. F, ImageJ analysis of the lanes after crosslinking, with the intensity calculated as 250 Gy value, normalized from 0 to 100, and the percentage of each species deduced from peak integration indicated under the respective peak.

The DNAJB6 C-terminal domain inhibits secondary nucleation

distribution centered around +5. Charging in electrospray is related to solvent-accessible surface area, and narrow low-charged distributions consequently correspond to well-ordered and compact protein structures with small solvent-accessible surface areas. The ion mobility of the +5 ions confirms a collision cross section in agreement with the published NMR structure of CTD (Fig. S3). The Rayleigh charge (Z_R) is the highest charge that a spherical droplet of a certain size can hold. Protein charge states higher than the Z_R of the protein cannot form from ionization of a compact folded structure and instead correspond to more extended structures (28, 29). Charge state analysis of the CTD proteins show charge states higher than +6, which are thus likely to represent such extended states for these proteins. The charge state of CTD STA is shifted toward higher charges, reaching all the way up to +8 (Fig. 2A). This indicates that the population of CTD STA is shifted toward more unstructured states compared with CTD, in agreement with its CD spectrum and its lower stability toward thermal denaturation (Fig. 2, B and C).

Oligomerization propensity of the CTD

Although both protein constructs are seen as mostly monomeric, a small population of dimers could be observed using native MS (Fig. 2C). This dimeric population was larger for CTD compared with CTD STA, indicating that the S/T->A amino acid residue substitutions affect also the propensity to dimerize. Also, hetero-CTD/CTD STA dimers do seem to form. These heterodimers are, however, shifted toward higher charge states compared with CTD homodimers, indicating a shift toward slightly more extended structures. The results regarding shifts in charge state, extendedness, and dimerization propensity were also confirmed using nonmixed samples of CTD and CTD STA (Fig. S3). Oligomerization was further studied using chemical crosslinking of samples containing 10 μ M of CTD or CTD STA in 20 mM sodium phosphate, 0.2 mM EDTA (pH 8.0), followed by SDS-PAGE and MS/MS analysis of the crosslinked peptides. This analysis reveals an increased oligomerization propensity of WT CTD compared with CTD STA. Both dimers and tetramers of CTD could be detected by SDS-PAGE (Fig. 2E) after crosslinking with the amine-reactive BS³ crosslinker, which crosslinks lysine residues within ca. 30 Å, corresponding to slightly more than the diameter of a CTD monomer, whereas CTD STA only displayed a weak band corresponding to the dimeric species and mainly a monomeric band. The oligomerization propensity and polydispersity of CTD is significantly lower than for full-length DNAJB6 (13).

Based on the integrated intensity of gel bands corresponding to monomers, dimers, and tetramers (Fig. 2F), and the total concentration of each construct (10 μ M), the concentration of each species was calculated assuming equal staining per monomer in each species. The analysis further assumes that the crosslinking reaction is fast compared with monomer-dimer and dimer-tetramer exchange. If not, the estimates for K_D represent lower bounds of their values (upper bound of the affinity). We can thus estimate the dimer-to-monomer equilibrium dissociation constant ($K_D = [\text{monomer}]^2/[\text{dimer}]$) to $K_D \geq 30 \mu\text{M}$ ($=5.5^2 \mu\text{M}/1.05$) for CTD and $K_D \geq 600 \mu\text{M}$ ($=9.7^2 \mu\text{M}/0.15$) for CTD STA and the tetramer-to-dimer equilibrium dissociation constant ($K_D = [\text{dimer}]^2/[\text{tetramer}]$) to $K_D \geq 2 \mu\text{M}$ ($=1.05^2 \mu\text{M}/0.6$) for CTD. LC-MS/MS analysis of the excised dimeric CTD band leads to identification of a crosslink between K189 and K189, thus crosslinking β -strand 1 in one monomer with β -strand 1 in the other monomer in the dimer. The K189-K189 crosslink was also observed in tetrameric CTD, as well as additional crosslinks within 30 Å distance, between K189 and K225 and between K196 and K225 in β -strand 4. The detected crosslinked peptides are presented in Table 1. A prediction of the dimeric CTD structure using AlphaFold2 suggests an interaction between β -strand 1 in each monomer in an antiparallel arrangement (Fig. S4, A-C). We also find that AlphaFold modeling predicts that dimerization is impeded by the S/T->A substitutions (Fig. S4, D-F).

Antiamyloid activity

The effect of CTD on A β 42 amyloid formation was examined by studying the spontaneous time-dependent aggregation of highly pure recombinant A β 42 *via* the fluorescence intensity of the amyloid-specific dye ThT. ThT increases its quantum yield upon binding to amyloid structures (30), which makes it suitable as a reporter probe for amyloid formation. A reaction half time ($t_{1/2}$) of approximately 1.5 h was observed for a sample of 3 μ M A β 42, in agreement with previous data at similar conditions (19). The effect of CTD and CTD STA was evaluated by varying their concentration while keeping the A β 42 concentration fixed at 3 μ M. Addition of CTD or CTD STA at CTD:A β 42 M ratios from 0.05:1 to 1:1 caused concentration-dependent retardation with the main effect being a change in slope of the transition (Fig. 3, A and B). CTD at a substoichiometric 0.5:1 M ratio increased $t_{1/2}$ by almost 10-fold compared with A β 42 alone. Cryo-EM analyses of samples taken at the final plateau confirm the formation of fibrils in samples both without and with CTD (Fig. S6, A and B). The fibrils formed in the presence of CTD do, however, appear

Table 1
Detected crosslinks in bands corresponding to CTD dimer and CTD oligomer

Sample	Precursor mass	Charge	Score	Crosslinked peptides	Lys A ^a	Lys B ^a
CTD dimer	958.172	3+	20.1	KSISTSTKMOVNGR + KSISTSTKMK	K189	K189
CTD tetramer	958.172	3+	17.6	KSISTSTKMOVNGR + KSISTSTKMK	K189	K189
	683.956	5+	24.8	KSISTSTKMOVNGR + VEVEEDGQLKSLTINGK	K189	K225
	658.337	6+	24.1	SISTSTKMOVNGR + VEVEEDGQLKSLTINGK	K196	K225

^a Lysine residue numbers refer to the number in full-length DNAJB6. Approved MS/MS spectra to validate the crosslinks are supplied in Fig. S5, A-D.




Figure 3. Anti-amyloid activity of C-terminal domain (CTD) constructs and DNAJB6. Time-dependent measurements of thioflavin T (ThT) fluorescence to follow the aggregation of 3 μM A β 42 alone (black) and in the presence of CTD (blue shades; (A)), CTD STA (red shades; (B)) or full-length DNAJB6 (silver-gold; (C)) in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0 with the color codes for the additive concentration given in each panel. The data in C are from Ref. (28). A β , amyloid- β .

longer and thinner and with longer twist distance than those formed from A β 42 alone. The effect of CTD STA is different from that of CTD with a combined effect on the length of the lag phase and the slope of the transition. Clearly, for both CTD and CTD STA, the effect on curve shape is very different, and the concentration ratio required for a significant effect is higher compared with full-length DNAJB6 (Fig. 3C). DNAJB6 causes a delay of the aggregation curve with retained steepness of the transition, and DNAJB6:A β 42 M ratios of as little as 0.005 to 0.04:1 leads to 10- to 100-fold increases in the $t_{1/2}$ at similar solution conditions as used here (5, 6, 31).

Kinetic analysis

The ThT fluorescence intensity for all replicates at each concentration of each construct was normalized and included in the kinetic analysis using the integrated rate laws for fibril growth as described earlier (19, 29). Initial fitting to all data obtained in the presence of each construct was performed three times using as a single variable parameter either the rate constant for primary nucleation, k_n , secondary nucleation, k_2 , or elongation, k_+ , based on Equation 1 with $[M]_0 = 0$ (non-seeded experiments). In each of these three attempts, the remaining two parameters were fixed at the values previously obtained for A β 42 alone (14). For CTD, we find that the analysis using k_2 as a variable parameter fits the data significantly better than the other two options (k_n or k_+ variable; Fig. S7). The improvement in the error square sum is a factor of 16 relative to k_n and a factor of 6 relative to k_+ . For CTD STA, the analysis using k_+ as a variable parameter fits the data better than the other two options (k_n or k_2 variable; Fig. S8). The improvement in the error square sum is a factor of 8 relative to k_n and a factor of 2 relative to k_2 . The kinetic analysis of data from nonseeded experiments is only reliant on the products $k_+ k_2$ and $k_+ k_n$ (Equations 2 and 3). Seeding experiments were therefore carried out in order to distinguish between effects on k_+ and k_2 . Aggregation reactions starting from A β 42 monomer plus preformed seeds at four defined seed concentrations (0.3, 1, 30, and 50% in monomer units) were used to probe the effect of each construct on mainly

secondary nucleation (0.3 and 1% seed) or on mainly elongation (30 and 50% seed). The data obtained at low seed concentration show a clear retardation and change in slope of the transition, implying very clearly that the rate of secondary nucleation is reduced although the effect may be slightly lower for CTD STA compared with CTD (Fig. S9A). The data obtained at 50% seed show that there is an additional effect on elongation, most prominently not only for CTD STA but also for CTD (Fig. S9B). From the initial rate at 50% seed, we can estimate the effect on k_+ for each construct as a function of its concentration.

A final kinetic analysis of data from nonseeded reactions was performed using the information from the analysis of the reactions with 50% seeds. In this analysis, we used the value of k_+ at each construct concentration as a fixed curve-specific parameter, k_n as a fixed global parameter, and k_2 as the curve-specific fitted parameter. This analysis provides an improved representation of the nonseeded data compared with variation of k_2 alone and allows us to discern for each construct the relative effect on k_2 and k_+ as a function of construct concentration. This final analysis of the data from nonseeded experiments is shown in Figure 4 and is found to result in improved or much improved fits compared with the analysis with a single affected rate constant. There is no remaining discrepancy that would support an effect on k_n for any of the constructs.

For CTD, the fit with k_2 as the single variable parameter is relatively good (Fig. S7), but the fit improves by using the variation in k_+ as inferred from the 50% seed experiment (Fig. 4A). The effect on k_2 clearly dominates over the effect on k_+ (Fig. 4C); the effect on k_2 is 100- to 1000-fold higher than the effect on k_+ at the highest CTD concentrations tested (0.75–3 μM). The combined analysis with both nonseeded and seeded data thus confirms that for CTD the effect on secondary nucleation strongly dominates.

For CTD STA, the analysis with a single variable rate constant produces a slightly better fit to the data with variation of k_+ compared with variation of k_2 (Fig. S8); still none of these options are very good. The fit to the data improves significantly if we use the variation in k_+ as inferred from the 50%

The DNAJB6 C-terminal domain inhibits secondary nucleation




Figure 4. Kinetic analyses of nonseeded data for A β 42 in the presence of C-terminal domain (CTD). Final analysis of data from nonseeded experiments for A β 42 in the presence of CTD (A and C) or CTD STA (B and C), using the construct-concentration-dependent values of k_+ from fits to data from 50%-seeded experiments and k_2 as a fitted parameter. Fits to data are shown in (A and B), and the effect on k_+ and k_2 is shown in (C) as averages and standard deviation over 12 replicates at each inhibitor concentration. The data were obtained at 37 °C, whereas the results obtained at 15 °C are shown in Fig. S10. A β , amyloid- β .

seed experiment and then fit k_2 to the data at each CTD STA concentration (Fig. 4B). The effects on k_+ and k_2 are compared in Figure 4C. The effect on k_2 is ca. 10-fold higher than the effect on k_+ at the three highest CTD STA concentrations tested (0.75–3 μ M). The combined analysis thus implies that for CTD STA the effect on secondary nucleation dominates over the effect on elongation. Given that the effect of reduced k_2 on the aggregation curve shape does not change very much beyond a 100-fold reduction and not at all after a 1000-fold reduction (32), the difference between CTD and CTD-STA at the highest three concentrations should be interpreted with caution.

The whole experiment was repeated three times at 37 °C, with four replicates of each inhibitor concentration in each repeat. The experiment was also repeated three times at 15 °C, with four replicates of each inhibitor concentration in each repeat, as both CTD and CTD STA are close to fully folded at this lower temperature (Fig. 2C). The data are shown in Fig. S10, A and B together with fits assuming selective reduction of secondary nucleation. These fits were motivated by the data under high seeding conditions (50% seed), which show no effect on the elongation rate of any of the two constructs at 15 °C (Fig. S10C). The effect of k_2 is plotted *versus* inhibitor concentration in Fig. S10D.

Interaction between CTD and A β 42 aggregates

Inhibition of secondary nucleation could be due to interactions with the amyloid fibril surface (Fig. 5A). The interaction between CTD and immobilized A β 42 fibrils was studied using surface plasmon resonance (SPR) technology. Injection of CTD resulted in a change in refractive index close to the surface indicative of an interaction with the fibrils, and an association phase clearly dependent on the injected construct concentration was observed (Fig. 5B). The data are indicative of relatively fast exchange rates (see Table S1 for fitted parameters) and a moderate affinity with an equilibrium association constant K of around 10^5 M $^{-1}$. The data for CTD STA are highly similar to those for CTD, indicating that the ST/A substitutions do not affect the affinity for A β 42 fibrils. No binding to a control surface without immobilized fibrils was observed. We also studied the possible complex formation

between CTD and A β 42 during an ongoing aggregation reaction using MS. Direct native MS analysis shows that coin-cubation of CTD with A β 42 results in a noticeable decrease in the amount of observed CTD homodimers.

The occurrence of A β 42–CTD complexes was also confirmed using native MS. A small fraction of A β 42–CTD heterodimers could be detected. A relatively high collisional activation was, however, required to obtain sufficient signal intensity as well as to detect any larger A β 42 oligomers or A β 42–CTD coaggregates (Fig. 5C). By MS–MS, we did not detect any crosslinks between A β 42 and CTD but between A β 42 and the CTD within intact DNAJB6 (Fig. S11, A–C and Table S2). Both A β 42–CTD and A β 42–CTD STA heterooligomers were detected upon increased collisional activation, indicating that both variants may interact with A β 42. The conditions are similar to those needed to detect A β 42 oligomers or coaggregates upon coin-cubation with micelles (33, 34), indicating that declustering of larger coaggregates is taking place. This would point toward interactions between A β 42 and CTD in higher order aggregation states instead of small heterooligomers.

CTD segments grafted to S100G

In order to study the functional role of β -strand 1 in CTD, we produced constructs with smaller parts of the CTD. S100G-CTD β 1–2 contains β -strand 1 and 2 (residues 187–212) and S100G-CTD β 1–4 four β -strands (residues 187–231) grafted between the two EF-hands of human S100G (Fig. 6A). These constructs thus lack the very C-terminal end of the CTD and were produced as WT and the corresponding ST/A-substituted variants. AlphaFold2 predicts that the original β -sheet architecture may form between the two EF-hands (Fig. 6A), and the predicted structural elements are all in excellent agreement with the experimentally solved NMR structures for S100G (Fig. S1, C and E) and CTD (Fig. S1, D and F). Far-UV CD spectroscopy further confirms a folded and mostly helical structure, with more negative ellipticity at 220 nm compared with the parent protein S100G, which could be attributed to the grafted β -sheet segment from CTD (Fig. 6B). The experimental spectra are moreover in excellent agreement with theoretical CD spectra generated from the AlphaFold models (Fig. 6C), indicating that the inserted loops




Figure 5. Characterization of interaction between C-terminal domain (CTD) constructs and Aβ42. A, the microscopic steps in amyloid formation that are used to fit the aggregation data Aβ42 data (top). Primary nucleation produces nuclei through interactions between monomers only, secondary nucleation produces nuclei from monomers catalyzed by fibrils, and elongation involves the growth of existing fibrils by addition of monomers. Modulation of these steps can arise because of interactions with different species (bottom). The formation of co-oligomers could decrease the rate of not only primary nucleation of pure fibrils but also secondary nucleation. Blocking the fibril surface or ends could decrease secondary nucleation and elongation, respectively. B, surface plasmon resonance (SPR) data in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0, 0.005% Tween-20, for the interaction of CTD with immobilized Aβ42 fibrils at 2 (light blue), 5 (medium blue), and 10 (blue) μM CTD (left) and the data obtained under buffer flow following the respective CTD injection (right). All data are shown with colors, and the fitted curves are shown in black. The corresponding SPR data for CTD STA are shown in Fig. S20. C, native MS data of Aβ42 that has been coincubated with CTD and CTD STA, measured at trap collision energies of 5 V (left) and 45 V (right). The homo Aβ42 oligomers are annotated by their oligomeric state/charge state (n/z) ratio. Heterooligomers are illustrated by symbols built up by Aβ42 (yellow square), CTD (blue circle), and CTD STA (red circle). Aβ, amyloid-β; MS, mass spectrometry.

of the produced constructs have folded into their intended β-sheet structures. Refolding of S100G after temperature-induced unfolding is fully reversible, whereas the insertion of CTD segments makes refolding almost fully reversible for S100G-CTDβ1–2 and less reversible for S100G-CTDβ1–4 (Fig. S2). The data further imply that the insertions of the CTD β-sheets destabilize S100G. The S100G-grafted constructs are, however, more stable than CTD (Fig. S2). The dimerization of the S100G-grafted constructs was studied using chemical crosslinking and SDS-PAGE (Fig. S12, A and B). As aforementioned, an upper limit for the affinity can be estimated based on the integrated intensity of gel bands corresponding to monomers and dimers and the total concentration of each construct (10 μM). For S100G-CTDβ1–2, we estimate the dimer-to-monomer equilibrium dissociation constant ($K_D = [\text{monomer}]^2/[\text{dimer}]$) to $K_D \geq 60 \mu\text{M}$ ($=8^2 \mu\text{M}/1$). For S100G-CTDβ1–4, the dimer band is very weak, and we can only estimate an approximate $K_D > 500 \mu\text{M}$ ($=9.6^2 \mu\text{M}/0.2$) meaning at least a factor of 8 lower dimerization affinity compared with S100G-CTDβ1–2. For the alanine-substituted grafts, the dimer band is extremely weak, thus K_D appears to be at least 1 mM. MS–MS analysis of S100G-CTDβ1–2 identified the K189–K189 crosslink in the formed dimers (Fig. S12C).

S100G is a Ca^{2+} -binding protein, also known as calbindin $\text{D}_{9\text{k}}$, with one Ca^{2+} -binding site in each EF-hand, which are energetically coupled, resulting in a positive cooperativity of

Ca^{2+} binding. The destabilizing effect of grafting the CTD β-strands could thus also be studied by measuring the Ca^{2+} -binding affinity and cooperativity of the constructs (Fig. S13). The larger graft in S100G-CTDβ1–4 caused a minor perturbation of the Ca^{2+} -binding function. The data follow a sigmoidal trend of the same sign as the parent protein but more shallow. Fitting Supplementary Equations 8 and 9 to the data reveals that the average Ca^{2+} affinity (average $\text{lg}K_{\text{av}} = 8.0$) is within a factor of 2 from S100G (average $\text{lg}K_{\text{av}} = 8.3$), but the level of positive cooperativity seems to be reduced ($-\Delta\Delta G_{\eta=1} = 1.4 \text{ kJ/mol}$) compared with S100G ($-\Delta\Delta G_{\eta=1} = 9 \text{ kJ/mol}$). The smaller graft in S100G-CTDβ1–2 l caused a major perturbation of Ca^{2+} binding. While the affinity (average $\text{lg}K_{\text{av}} = 7.8$) is only reduced by a factor of 3, the affinity for the first-bound Ca^{2+} ion ($\text{lg}K_1 = 8.5$) is significantly higher than for the second-bound Ca^{2+} ion ($\text{lg}K_2 = 7.0$) implying that the positive cooperativity is lost. Thus, for both grafts, the effect on the average Ca^{2+} affinity is small, but the positive cooperativity of binding is reduced, implying that the communication between the two EF-hands is affected by insertion of the β-strands.

Antiamyloid effect of the β-sheet grafts

Both S100G-CTDβ1–2 and S100G-CTDβ1–4 as well as their corresponding ST/A-substituted variants display anti-amyloid activity observed as a prolonged Aβ42 aggregation

The DNAJB6 C-terminal domain inhibits secondary nucleation




Figure 6. Structure and antiamyloid activity of S100G-CTD constructs. *A*, architecture of S100G-CTD β 1-4 (top) and S100G-CTD β 1-2 (bottom) with the β -strands from CTD grafted between the two EF-hands of S100G. AlphaFold2 predictions (top three ranks) for the two constructs are shown colored according to their pLDDT scores (red to blue). *B*, experimental far-UV CD spectra of S100G-CTD β 1-2 (purple) and S100G-CTD β 1-4 (orange) at 5 °C (solid line) and at 95 °C (dashed line). *C*, predicted far-UV CD spectra for the top ranked AlphaFold2 models of S100G-CTD β 1-2 (purple) and S100G-CTD β 1-4 (orange), predicted using PDBMD2CD (<https://pdbmd2cd.cryst.bbk.ac.uk>). *D*, time-dependent ThT kinetics data for A β 42 (3 μ M) aggregation in the presence of increasing concentration of S100G-CTD β 1-4 in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0. The fits are from the final analysis of data from nonseeded experiments using the construct-concentration-dependent values of k_1 from fits to data from 50%-seeded experiments and k_2 as a fitted parameter. *E*, time-dependent ThT kinetics data for A β 42 (3 μ M) aggregation in the presence of increasing concentration of S100G-CTD β 1-2 (left) or the S100G-CTD β 1-2Scr variant where the sequence of the grafted CTD segment in S100G-CTD β 1-2 has been scrambled (right) in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0. The AlphaFold2 prediction (top three ranks) of the S100G-CTD β 1-2Scr construct is also shown colored according to their pLDDT scores (red to blue). For the data on S100G-CTD β 1-2, the fits are from the final analysis of data from nonseeded experiments using the construct-concentration-dependent values of k_1 from fits to data from 50%-seeded experiments and k_2 as a fitted parameter. CTD, C-terminal domain; ThT, thioflavin T.

time in ThT kinetics experiments. Especially, the slope of the transition is reduced, and the data are best fitted assuming a reduction of the rate constant for secondary nucleation (Figs. 6, D and E and S14–S17). Cryo-EM analyses of samples taken at the final plateau confirm the formation of fibrils in samples with S100G-CTD β 1-2 or S100G-CTD β 1-4 (Fig. S6, C and D). The A β 42 aggregation kinetics in the presence of an S100G control protein was also measured in order to test if this antiamyloid effect is due to the grafted β -strands from DNAJB6 or simply an effect of the S100G scaffold. It is known that globular proteins can delay amyloid aggregation by nonspecific interactions (35) and that these effects have a strong charge dependence (36). Therefore, an S100G variant with a net charge of -4 at pH 8, because of the mutations E17Q + D19N + E26Q, was used. This can be compared with the net charge of -2 for S100G-CTD β 1-2 and -5 for S100G-CTD β 1-4 at pH 8. The effect of two positively charged proteins scMn+8 (net charge $+8$) (37) and chicken lysozyme (net charge $+9$) were also studied. The uneven charge distribution in S100G-CTD β 1-2 prompted the investigation of a second control protein, S100G-CTD β 1-2Scr with the same amino acid residue composition as S100G-CTD β 1-2 but with the sequence of the inserted β 1-2 loop scrambled (Fig. S1). AlphaFold prediction yielded a structure model of S100G-

CTD β 1-2Scr where the inserted scrambled loop has the lowest possible prediction score (<50) and is modeled as an unstructured segment (Fig. 6E). Low prediction scores in AlphaFold have been shown to be an indicator of disorder (38), and the prediction of an unfolded loop was confirmed using CD spectroscopy where the experimental spectrum agreed nicely with the predicted spectrum for the AlphaFold model (Fig. S2F). The S100G-CTD β 1-2Scr displayed only a minor antiamyloid activity (Fig. 6F), whereas the positively charged control proteins displayed a strong retardation and the S100G-4 variant displayed no activity (Fig. S18). This indicates that the antiamyloid activity of the two S100G-CTD constructs is likely because of the folded β -strands from DNAJB6, rather than because of S100G or nonspecific protein charge effects. The similar effects of the two S100G-CTD constructs indicate further that the first β -hairpin (β 1 and β 2) is sufficient for the antiamyloid activity observed for the CTD.

The effects on the ThT kinetics by the S100G-grafted constructs are qualitatively similar to the effects observed for CTD in that the main effect is a reduced slope of the transition. The concentration-dependent reduction of the slope, and the resulting increase in $t_{1/2}$ is, however, not as pronounced as for CTD. Fitting to the data, in the same way as described for aforementioned CTD, reveals that the antiamyloid activity is

mostly because of inhibition of secondary nucleation, with an additional small effect on the elongation rate in the case of S100G-CTD β 1–4 (Figs. S14–S17). The data together with the final fit to data from nonseeded reactions using information from seeded ones are shown in Figure 6D for S100G-CTD β 1–4 and in Figure 6E for S100G-CTD β 1–2. Binding of the S100G-grafted constructs to A β 42 fibrils was observed using SPR (Fig. S19). The affinities of S100G-CTD β 1–2 and S100G-CTD β 1–4 for the fibrils were 3 to 100 times higher than for CTD, with equilibrium constant, K , of $3 \times 10^5 \text{ M}^{-1}$ and $1 \times 10^7 \text{ M}^{-1}$, respectively. The data for S100G-CTD β 1–4STA are highly similar to those for S100G-CTD β 1–4, and the data for S100G-CTD β 1–2STA are highly similar to those for S100G-CTD β 1–4. No binding to control surfaces with immobilized monomers, or no immobilized protein, was observed. The fitted parameters are found in Table S1.

Discussion

Protein aggregation and amyloid formation are occurring continuously in living systems. The maintenance of proteostasis (protein homeostasis) requires many chaperones and protein quality control systems that uphold the delicate balance between protein synthesis, folding, and degradation (39, 40). When proteostasis is declining in performance, synthesized proteins may not fold efficiently, metastable proteins lose their functionally active conformations, and cytotoxic protein aggregates accumulate, which is associated with many age-dependent neurodegenerative diseases. In case of Alzheimer's disease, associated with the amyloid formation of A β peptide herein investigated, recent data from complex *in vivo* studies in new neuronal model systems suggest lysosomal quality control deficits in diseased neurons (41, 42). A number of different chaperones may inhibit amyloid formation (1–11, 43–47). The mechanism of amyloid formation has been extensively studied *in vitro* for several proteins, revealing a conformity in terms of underlying steps; in principle, for all systems studied, there appears to be primary and secondary nucleation, elongation, and in some cases, also fragmentation. The relative rate constants of these steps and thereby step dominance varies between systems, yet the set of steps is retained, for example, in the case of A β 42 in buffer (14) and in CSF (26). While studies of amyloid mechanisms *in vivo* are emerging (48–50), a detailed investigation *in vitro* can provide information of which steps are affected by an inhibitor. Parallel studies of a set of antibodies revealed for each antibody that the same steps are affected in buffer and CSF (27).

Shift of inhibitory mechanism

The results of the current study imply that the isolated CTD of the DNAJB6 chaperone, or constructs containing β -strands 1 and 2 from this domain, display anti-amyloid activity toward A β 42 aggregation *in vitro*. This activity is, however, different from that of full-length DNAJB6, with a distinct shift of inhibition mechanism. DNAJB6 strongly reduces the rate of primary nucleation and has an effect also on the rate of secondary nucleation (5), leading to a very large extension of the

lag phase. In contrast, all three constructs studied here—and their respective STA controls—seem to mainly decrease the rate of secondary nucleation, leading to a reduced slope of the transition. The inhibition of secondary nucleation by the CTD is approximately as efficient as previously observed with the Brichos domain (47) and with fibril-binding proteins derived by phage display (32). Some of the constructs also show an additional small effect on elongation seen as a minor extension of the lag phase and a change in curve shape.

It should be noted that full-length DNAJB6 decreases the rate of secondary nucleation to approximately the same extent as the CTD at low client:chaperone ratios (5), indicating that the CTD has lost the ability of the full-length proteins to inhibit primary nucleation but retained its ability to inhibit secondary nucleation. This suggests that another part of DNAJB6 is responsible for primary nucleation inhibition, or that synergistic effects between CTD and other parts of DNAJB6 are required for such activity.

Altered mode of interaction

Potent inhibition of A β 42 aggregation is a feature observed for many chaperones (5, 6, 44, 47, 51). A shift in mechanism, in terms of which microscopic step(s) are modulated by an inhibitor, may be related to a shift in the mode of interaction, in terms of which species the chaperon or domain interact with (Fig. 5A; (52, 53)). Interactions with monomers may lead to inhibition of not only primary nucleation but also secondary nucleation and elongation because the monomer is a reactant in these steps as well. Interactions with oligomers, or the formation of co-oligomers at the expense of pure amyloid peptide oligomers, may lead to inhibition of not only primary nucleation but also secondary nucleation. Interactions with fibril surfaces may block the catalytic sites for secondary nucleation, and interactions with fibril ends may interfere with elongation. For DNAJB6, an interaction with A β 42 oligomers or the formation of co-oligomers at the expense of pure A β 42 oligomers may explain its potency to inhibit primary nucleation of A β 42 fibrils (5, 6). The current SPR and native MS results suggest that CTD, as well as the S100G with grafted segments from CTD, interact with fibrils but not with small oligomers of A β 42. The observed inhibition of A β 42 secondary nucleation by CTD and the grafts is therefore most likely because of an interference with the catalysis at the fibril surface. The current data thus suggest that the inhibition of secondary nucleation by DNAJB6 can be ascribed to its CTD, whereas the inhibition of primary nucleation is a feature of the rest or the whole protein.

The role of the Ser/Thr to Ala substitutions, CTD stability, and dimerization

The five STA mutations were incorporated in CTD as well as in the grafts S100G-CTD β 1–2 and S100G-CTD β 1–4 because these five substitutions have been found to reduce the potency of DNAJB6 in the inhibition of primary nucleation (5, 6, 31). However, these substitutions have less effect on the potency of CTD to inhibit secondary nucleation, suggesting that the role of Ser190, 192, 194 and Thr 193, 195 in the first β -

The DNAJB6 C-terminal domain inhibits secondary nucleation

strand of CTD is not the same in the inhibition of primary and secondary pathways.

The thermal denaturation midpoint, T_m , is reduced by 19 °C, from 58 °C for CTD to 39 °C for the STA variant, and the CD spectra indicate that CTD STA on average contains less β -sheet than CTD, reflecting a larger population of unfolded protein (Fig. 2, B and C). This is corroborated by the native mass spectra, which show an increased population of highly charged states for CTD STA compared with CTD. The replacement of five hydrophilic side chains with the hydrophobic alanine thus favors the unfolded over the folded form, meaning alanine either destabilizes the folded form or stabilizes the unfolded form of CTD. The shift in stability may reflect a reduced equilibrium constant for dimerization, which is energetically coupled to the folding–unfolding equilibrium. The crosslinking experiments indeed reveal a reduced population of dimers for CTD STA compared with CTD, implying a reduced monomer–dimer equilibrium constant for the mutant. From the fitted denaturation parameters (Fig. 2, B and C), we can estimate that the fraction of unfolded protein is ca. 5% for CTD and 45% for CTD STA at the temperature of the aggregation experiments (37 °C). The kinetic analysis suggests that CTD has a small effect also on elongation, and this effect is more prominent for CTD STA, although for both variants, the effect on secondary nucleation dominates (Fig. 4). It is thus possible that the folded CTD interacts with fibril surfaces blocking secondary nucleation and the unfolded monomers interact with fibril ends reducing the rate of elongation. The fibril end exposes the hydrophobic core of the terminal monomer plane, which may explain the increased effect on elongation of the more hydrophobic CTD STA compared with CTD. This interpretation is strengthened by the data at 15 °C, under which condition, both variants are close to fully folded, no effect on elongation is found, and both variants exclusively inhibit secondary nucleation (Fig. S10). At 15 °C, the aggregation of A β 42 is even more dominated by secondary nucleation compared with 37 °C (15); it thus emerges that CTD STA may be a more effective inhibitor of secondary nucleation than CTD, in clear contrast to WT DNAJB6 being a more effective inhibitor of primary nucleation than DNAJB6 with the same STA substitutions (6).

The role of CTD net charge

Many proteins have been found to delay amyloid aggregation (35), and these effects have a strong charge dependence with stronger inhibition the higher the net charge, that is, more positive for positively charged proteins and less negative for negatively charged proteins (36). The CTD (and CTD STA) monomer has a net charge of +3 over 56 residues at pH 8.0 (assuming charged ends), that is, +0.5 per kDa. It is therefore relevant to ask whether fibril binding and the effect on secondary nucleation is a specific feature of CTD, or whether this activity is a consequence of its positive net charge. The single-chain variant of the plant protein monellin with net charge +8 (scMN+8; +0.7 per kDa) (37) and chicken lysozyme with net charge +0.5 per kDa are both very potent inhibitors of A β 42

aggregation at the same series of concentrations as used for CTD and CTD STA (Fig. S18). Indeed, the effect of lysozyme, with the same charge density, is indistinguishable from that of CTD, whereas the more highly charged scMN+8 is even more retarding. The large anti-amyloid effect of these control proteins raises intriguing questions regarding the uneven charge distribution in DNAJB6. Since the net charge of DNAJB6 is close to zero around pH 8, its charge distribution around this pH can be estimated using a titration profile based on model pK_a values and ideal titration curves (54) (Fig. S21). While the total number of charged residues is high in both globular domains, they are predicted to carry a few units of net positive charge at pH 8 and connected by a negatively charged linker leading to an overall charge close to zero.

The S100G variant with net charge -4 displays no anti-amyloid activity (Fig. S18), indicating that the effects of S100G-CTD β 1–4 (net charge -5) and S100G-CTD β 1–2 (net charge -2) are due to the β -strands of CTD rather than nonspecific protein charge effects. This -4 variant has a relatively uniform charge distribution over one domain, whereas each of S100G-CTD β 1–4 and S100G-CTD β 1–2 has one negative (-7) and one positive ($+2$ or $+5$) domain. Polarized charge interactions could therefore be possible in these cases. However, the S100G-CTD β 1–2Scr variant displayed very low anti-amyloid activity (Fig. 6E). This variant has the same charge polarization as S100G-CTD β 1–2 but does not form the folded DNAJB6 β -hairpin structure as the sequence is scrambled. This indicates that the observed effects on amyloid aggregation by the CTD constructs are due to specific interactions involving the CTD β -sheet, rather than nonspecific charge effects.

The role of β -strand 1 in CTD

AlphaFold predicts that the interaction between two CTD monomers in the homodimer involves the two copies of β -strand 1 from the two monomers in an antiparallel arrangement leading to a 10-stranded β -sheet involving both monomers (Fig. S4). While the large distance allowance (30 Å) of the crosslinker used could in principle link any pair of lysines in a dimer, the K189–K189 crosslink clearly dominates (Fig. 2D and Table 1), implying that this pair of lysine side chains reacts more easily than other pairs in the formed dimer. This is corroborated by the AlphaFold prediction, in which the two K189 side chains are indeed on the same face of the 10-stranded β -sheet, whereas K189 in one monomer and K196 in the other monomer, although as close in space, are placed on opposite faces of the sheet (Fig. S4). A corresponding crosslink analysis of S100G-CTD β 1–2 again identified the K189–K189 crosslink in the formed dimers (Fig. S12C). The apparently lower dimer affinity for S100G-CTD β 1–4 compared with S100G-CTD β 1–2 could have many molecular origins, and the small free energy difference ($\Delta\Delta G \geq 6$ kJ/mol) may indeed not be larger than what is seen upon removal of a single methylene group at a hydrophobic interface (55).

β -strand 1 in CTD has been hypothesized to interact with A β based on reduced inhibitory potency of full-length DNAJB6 with substitutions in this strand (6). Contacts between

β -strand 1 in CTD and A β 42 are predicted by an AlphaFold model of a CTD-A β 42 heterodimer (Fig. 5D) and is detected in crosslinking experiments with full-length DNAJB6 but not with the CTD construct (Table S2). The similar effects on secondary nucleation by S100G-CTD β 1–2 and S100G-CTD β 1–4, and the lack of effect by S100G-CTD β 1–2Scr, imply that β -strands 1 and 2 are sufficient for the antiamyloid effect in the grafts.

The role of chaperone chemical potential

The discrepancy between the large effect of the STA substitutions in β -strand 1 of DNAJB6 on the one hand (5, 31) and the lack of effect of the same substitutions in CTD or the grafts on the other hand raises the question of whether the five Ser and Thr residues play additional roles than in direct interaction with client peptides. An alternative mechanism behind the antiamyloid activity and suppression of primary nucleation of A β 42 fibril formation by DNAJB6 may be an unusually high chemical potential of the chaperone (56). In such mechanism, the chemical potential of the chaperone would be significantly reduced upon formation of coaggregates with A β 42, in which the amyloid peptide may gain a higher chemical potential compared with pure amyloid fibrils. This would cause a shift in the amyloid formation equilibrium toward a higher solubility of A β 42 (56), as is indeed observed (6). The fact that the five S/T substitutions make DNAJB6 a less potent inhibitor of primary nucleation and a less efficient enhancer of A β 42 solubility suggests that these substitutions may potentially affect the antiamyloid function of DNAJB6 by lowering its chemical potential, thus making it less prone to form coaggregates with client peptides. In contrast, CTD and the two grafted constructs seem to behave more like regular folded proteins, implying that the high chemical potential of DNAJB6 is either a feature of the entire protein or of the missing unstructured linker and/or JD. This is supported by the observation that the nonoligomeric DNAJB6 Δ S/T variant affects A β 42 aggregation in qualitatively similar ways as CTD, with a decrease in the rate constant for secondary nucleation without a significant change in primary nucleation (6).

The role of chaperone oligomers

Like amyloid proteins (57), many chaperones are prone to self-assembly. There is an intriguing correlation between oligomerization of DNAJB6 and its potency as an antiamyloid chaperone. For example, substitutions that render the chaperone less oligomeric also interfere with its effect on aggregation kinetics and amyloid peptide solubility (6, 22). However, DNAJB6 is active as a chaperone at concentrations well below its critical aggregation concentration. Ultrapure DNAJB6 preparations may for example significantly inhibit the aggregation of 3 μ M A β 42 at 15 nM DNAJB6 (10-fold increase in $t_{1/2}$) (31), whereas the critical aggregation concentration was recently found to be around 100 nM (58). Oligomerization and amyloid inhibition may thus be two consequences of the same chaperone property. This property may be a high chemical potential of DNAJB6, which it can lower through coassembly with client

peptides or through self-assembly with other copies of itself. The extreme polydispersity suggests that the chemical potential is high in oligomers of all aggregation numbers, that is, no self-assembly arrangement is significantly more stable than another one (56). The five S/T substitutions may potentially lower the chemical potential of DNAJB6, thus making it less prone both to coassemble with other proteins and to self-assemble. No large oligomers are observed for CTD, which in addition to monomers, is observed as a low population of dimers and tetramers reliant on the S/T residues in β -strand 1 (Fig. 2, E and F). This implies that the formation of large oligomers is reliant on other parts of DNAJB6 than CTD alone, as was aforementioned also concluded for its capacity to inhibit primary nucleation. The high chemical potential of DNAJB6 thus seems to be a feature governed by other parts of the full-length protein or a synergistic effect of both folded domains and the linkers.

Conclusions

The strong potency of DNAJB6 to inhibit primary nucleation at substoichiometric molar ratio is not seen with CTD or any of the S100G-CTD constructs, which, however, reduce the rate of secondary nucleation to a similar extent as DNAJB6. The formation of transient co-oligomers as between A β 42 and DNAJB6 is not observed between A β 42 and CTD or the S100G-CTD constructs. A third aspect of DNAJB6 not replicated by CTD or the S100G-CTD constructs is the formation of large and polydisperse oligomers. CTD forms dimers only weakly ($K = 3 \times 10^4 \text{ M}^{-1}$) and even weaker if five S/T residues in β -strand 1 are mutated to A. The shift in inhibitory mechanism seems to be due to binding of CTD to A β fibrils rather than oligomers, and fibril binding is apparently not reliant on these S/T residues. The inhibition of primary nucleation and the formation of large oligomers are thus two properties of DNAJB6, which are governed by other parts than CTD, or a synergistic effect of the entire DNAJB6 with its two folded domains and long unstructured linkers. Binding to A β 42 fibrils and inhibition of secondary nucleation can, however, be mimicked by the isolated CTD or even a construct that only contains the first two β -strands of the CTD, which affects the nucleation events at the fibril surface. The results of the current study thus show that the retardation of secondary nucleation by DNAJB6 can be ascribed to its CTD, whereas the inhibition of primary nucleation is dependent on the rest or all the protein.

Experimental procedures

All methods are described in detail in the [Supporting information](#) section.

Prediction of structures using AlphaFold

All predictions were generated using the online version AlphaFold2 with MMseqs2, no templates, within ColabFold (59). A pLDDT value <50 indicates poor prediction, and pLDDT >90 corresponds to high confidence (59, 60).

The DNAJB6 C-terminal domain inhibits secondary nucleation

Expression and purification of DNAJB6 constructs

The sequences of the DNAJB6-derived proteins are found in Fig. S1. All proteins were purified using sonication, boiling, ion exchange, and SEC, as further described in the Supporting information section. Chromatograms and SDS-PAGE gels from the purification procedures are found in Fig. S22 (CTD), Fig. S23 (S100G-CTD β 1–2), and Fig. S24 (S100G-CTD β 1–4). The purity of all constructs was >99% based on the absence of other bands in overloaded Coomassie-stained SDS-PAGE gels; no other peaks were observed in SEC chromatogram and MALDI mass spectra.

Expression and purification of A β 42

A β (M1-42), here called A β 42, was expressed and purified as described (14, 61) and stored as lyophilized aliquots after monomer isolation. The purity of A β 42 was >99.5% based on the absence of other bands seen on silver-stained SDS-PAGE gel, the absence of signals from molecules in an ^1H NMR spectrum; no other peaks were seen by SEC or in the MALDI mass spectrum. Monomers for the kinetics experiments were isolated from such aliquots using SEC 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0.

Expression and purification of S100G (E17Q + D19N + E26Q), scMn+8, and lysozyme

The S100G mutant E17Q + D19N + E26Q and scMn+8 were expressed and purified as described (62, 63). The purity was >99.5% based on the absence of other bands seen on silver-stained SDS-PAGE gels, the absence of signals from molecules in an ^1H NMR spectra; no other peaks were seen by SEC or in MALDI mass spectra. Chicken egg lysozyme was purchased from Sigma–Aldrich (NR) and purified by passing through an anion exchange resin to remove anionic contaminants. The purity was >99% based on the absence of other bands in overloaded Coomassie-stained SDS-PAGE gels, and no other peaks were observed by SEC. Each protein was subjected to SEC on Superdex 75 column to isolate pure monomer in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0 prior to use in the kinetic assays.

Native MS

Samples for native MS were buffer exchanged into 200 mM ammonium acetate (pH 6.8) to final protein concentrations of 10 to 25 μM . A β 42 and CTD constructs were coincubated for 10 min at 37 °C prior to native MS analysis. Cross-section measurements were obtained from calibration, with reference cross-section values obtained from the literature (64).

Chemical crosslinking MS

Samples were crosslinked and prepared for mass spectrometric analysis as described (18). Data acquisition and analysis was done as described (18), with details in the Supporting information section.

CD spectroscopy and thermal denaturation

CD spectra and thermal scans were recorded using a Jasco J-815 spectropolarimeter as described in the Supporting information section.

Prediction of CD spectra

Theoretical CD spectra were generated of the S100G-CTD constructs using the PDBMD2CD online software (65), as described in the Supporting information section.

Nonseeded and seeded aggregation kinetics

Aggregation kinetics experiments were set up in 96-well PEG-ylated polystyrene plates, black with transparent bottom (Corning; catalog no.: 3881) in 20 mM sodium phosphate, 0.2 mM EDTA, pH 8.0.

Kinetic analyses

Kinetic analyses of data were performed using the AmyloFit (amylofit.com) online software (66) and the following master equation that describes the time evolution of the fibril mass concentration, M .

$$\frac{[M]}{[M]_{\infty}} = 1 - \left(1 - \frac{[M]_0}{[M]_{\infty}}\right) * \left(\frac{B_+ + C_+}{B_- + C_+} * \frac{B_- + C_+ e^{\kappa t}}{B_+ + C_+ e^{\kappa t}}\right)^{\frac{k_{\infty}^2}{k_{\infty} \kappa}} e^{-k_{\infty} t} \quad (1)$$

where the parameters are defined as follows:

$$\kappa = \sqrt{2k_+ k_2 [m]_0^{n_2+1}} \quad (2)$$

$$\lambda = \sqrt{2k_+ k_n [m]_0^{n_c}} \quad (3)$$

$$C_{\pm} = \frac{k_+ [P]_0}{\kappa} \pm \frac{k_+ [M]_0}{2[m]_0 k_+} \pm \frac{\lambda^2}{(2\kappa^2)} \quad (4)$$

$$k_{\infty} = \sqrt{\frac{2\kappa^2}{[n_2(n_2+1)]} + \frac{2\lambda^2}{n_c}} \quad (5)$$

$$\bar{k}_{\infty} = \sqrt{k_{\infty}^2 - 4C_+ C_- \kappa^2} \quad (6)$$

$$B_{\pm} = \frac{k_{\infty} \pm \bar{k}_{\infty}}{2\kappa} \quad (7)$$

In these relations, $[m]_0$ is the initial monomer concentration, $[P]_0$ and $[P]_{\infty}$ are aggregate number concentrations at the start of the reaction and after reaction completion, respectively. $[M]_0$ and $[M]_{\infty}$ are the mass concentrations of fibrils at the start and end of the reaction, respectively. k_n , k_2 , and k_+ are the rate constants for primary nucleation, secondary nucleation, and elongation, respectively. n_c and n_2 are the monomer reaction orders of

primary and secondary nucleation, respectively. The values $n_c = 2$ and $n_2 = 2$ were fixed based on previous results for A β 42 (14).

Cryo-transmission electron microscopy

Cryo-transmission electron microscopy images were acquired using a JEM 2200FS electron microscope.

Ca²⁺ binding

The macroscopic Ca²⁺-binding constants, K_1 and K_2 , for S100G-CTD β 1–4 and S100G-CTD β 1–2 were determined from competitive Ca²⁺ titrations *versus* the chromophoric Ca²⁺ chelator Quin2 in 2 mM Tris–HCl, pH 7.5. The data were fitted as described in the Supporting information section.

Data availability

All data are contained within the article.

Supporting information—This article contains supporting information (59).

Author contributions—C. E. and S. L. conceptualization; N. Ö., C. E., and S. L. methodology; N. Ö., R. F., A. C., D. T., M. K., V. M., C. E., and S. L. validation; N. Ö., A. C., C. E., and S. L. formal analysis; N. Ö., R. F., A. C., D. T., M. K., V. M., C. E., and S. L. investigation; A. G. resources; N. Ö. and S. L. visualization; N. Ö., C. E., and S. L. writing—original draft; R. F., A. C., D. T., M. K., V. M., and A. G. writing—review & editing; A. G., S. L., and C. E. supervision; C. E. and S. L. project administration; N. Ö., A. G. and S. L. funding acquisition.

Funding and additional information—This work was funded by the Wenner-Gren Foundations (grant WGF2023-0001 to N. Ö.), the Swedish Research Council (grant 2015-00143; to S. L. and grant 2021-04744; to A. G.), the Knut and Alice Wallenberg Foundation (grant 2022.0059; to S. L.), and the European Research Council (grant 101097824; to S. L.).

Conflict of interest—S. L. is a founder and employee of Wren Therapeutics Ltd. The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: A β , amyloid- β ; CSF, cerebrospinal fluid; CTD, C-terminal domain; JD, J-domain; MS, mass spectrometry; SEC, size-exclusion chromatography; SPR, surface plasmon resonance; ThT, thioflavin T.

References

1. Faust, O., Abayev-Avraham, M., Wentink, A. S., Maurer, M., Nille-goda, N. B., London, N., *et al.* (2020) HSP40 proteins use class-specific regulation to drive HSP70 functional diversity. *Nature* **587**, 489–494
2. Hageman, J., Rujano, M. A., van Waarde, M. A. W. H., Kakkar, V., Dirks, R. P., Govorukhina, N., *et al.* (2010) A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. *Mol. Cell* **37**, 355–369
3. Nillegoda, N. B., Kirstein, J., Szlachcic, A., Berynsky, M., Stank, A., Stengel, F., *et al.* (2015) Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. *Nature* **524**, 247–251
4. Wentink, A. S., Nillegoda, N. B., Feufel, J., Ubartaitė, G., Schneider, C. P., De Los Rios, P., *et al.* (2020) Molecular dissection of amyloid disaggregation by human HSP70. *Nature* **587**, 483–488
5. Månsson, C., Arosio, P., Hussein, R., Kampinga, H. H., Hashem, R. M., Boelens, W. C., *et al.* (2014) Interaction of the molecular chaperone DNAJB6 with growing amyloid-beta 42 (A β 42) aggregates leads to substoichiometric inhibition of amyloid formation. *J. Biol. Chem.* **289**, 31066–31076
6. Månsson, C., Van Cruchten, R. T. P., Weininger, U., Yang, X., Cukalevski, R., Arosio, P., *et al.* (2018) Conserved S/T residues of the human chaperone DNAJB6 are required for effective inhibition of A β 42 amyloid fibril formation. *Biochemistry* **57**, 4891–4892
7. Månsson, C., Kakkar, V., Monsellier, E., Sourigues, Y., Härmark, J., Kampinga, H. H., *et al.* (2014) DNAJB6 is a peptide-binding chaperone which can suppress amyloid fibrillation of polyglutamine peptides at substoichiometric molar ratios. *Cell Stress Chaperones* **19**, 227–239
8. Kakkar, V., Månsson, C., de Mattos, E. P., Bergink, S., van der Zwaag, M., van Waarde, M. A. W. H., *et al.* (2016) The S/T-Rich motif in the DNAJB6 chaperone delays polyglutamine aggregation and the onset of disease in a mouse model. *Mol. Cell* **62**, 272–283
9. Rodríguez-González, C., Lin, S., Arkan, S., and Hansen, C. (2020) Co-chaperones DNAJA1 and DNAJB6 are critical for regulation of polyglutamine aggregation. *Sci. Rep.* **10**, 8130
10. Thiruvalluvan, A., de Mattos, E. P., Brunsting, J. F., Bakels, R., Serlidaki, D., Barazzuol, L., *et al.* (2020) DNAJB6, a key factor in neuronal sensitivity to amyloidogenesis. *Mol. Cell* **78**, 346–358.e9
11. Aprile, F. A., Källstig, E., Limorenko, G., Vendruscolo, M., Ron, D., and Hansen, C. (2017) The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress α -synuclein aggregation. *Sci. Rep.* **7**, 9039
12. Deshayes, N., Arkan, S., and Hansen, C. (2019) The molecular chaperone DNAJB6, but not DNAJB1, suppresses the seeded aggregation of alpha-synuclein in cells. *Int. J. Mol. Sci.* **20**, 4495
13. Österlund, N., Lundqvist, M., Ilag, L. L., Gräslund, A., and Emanuelsson, C. (2020) Amyloid- β oligomers are captured by the DNAJB6 chaperone: direct detection of interactions that can prevent primary nucleation. *J. Biol. Chem.* **295**, 8135–8144
14. Cohen, S. I. A., Linse, S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., *et al.* (2013) Proliferation of amyloid- β 42 aggregates occurs through a secondary nucleation mechanism. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 9758–9763
15. Cohen, S. I. A., Cukalevski, R., Michaels, T. C. T., Šarić, A., Törnquist, M., Vendruscolo, M., *et al.* (2018) Distinct thermodynamic signatures of oligomer generation in the aggregation of the amyloid- β peptide. *Nat. Chem.* **10**, 523–531
16. Jiang, Y., Rossi, P., and Kalodimos, C. G. (2019) Structural basis for client recognition and activity of Hsp40 chaperones. *Science* **365**, 1313–1319
17. Liu, Q., Liang, C., and Zhou, L. (2020) Structural and functional analysis of the Hsp70/Hsp40 chaperone system. *Protein Sci.* **29**, 378–390
18. Söderberg, C. A. G., Månsson, C., Bernfur, K., Rutsdottir, G., Härmark, J., Rajan, S., *et al.* (2018) Structural modelling of the DNAJB6 oligomeric chaperone shows a peptide-binding cleft lined with conserved S/T-residues at the dimer interface. *Sci. Rep.* **8**, 5199
19. Österlund, N., Vosselman, T., Leppert, A., Gräslund, A., Jörnvall, H., Ilag, L. L., *et al.* (2022) Mass spectrometry and machine learning reveal determinants of client recognition by anti-amyloid chaperones. *Mol. Cell. Proteomics* **21**, 100413
20. Wu, Y., Li, J., Jin, Z., Fu, Z., and Sha, B. (2005) The crystal structure of the C-terminal fragment of yeast Hsp40 Ydj1 reveals novel dimerization motif for Hsp40. *J. Mol. Biol.* **346**, 1005–1011
21. Sha, B., Lee, S., and Cyr, D. M. (2000) The crystal structure of the peptide-binding fragment from the yeast Hsp40 protein Sis1. *Structure* **8**, 799–807
22. Karamanos, T. K., Tugarinov, V., and Clore, G. M. (2019) Unraveling the structure and dynamics of the human DNAJB6b chaperone by NMR reveals insights into Hsp40-mediated proteostasis. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 21529–21538
23. Karamanos, T. K., Tugarinov, V., and Clore, G. M. (2020) An S/T motif controls reversible oligomerization of the Hsp40 chaperone DNAJB6b

The DNAJB6 C-terminal domain inhibits secondary nucleation

- through subtle reorganization of a β sheet backbone. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 30441–30450
24. Cawood, E. E., Clore, G. M., and Karamanos, T. K. (2022) Microsecond backbone motions modulate the oligomerization of the DNAJB6 chaperone. *Angew. Chem. Int. Ed. Engl.* **61**, e202116403
 25. Aslam, M., Kandasamy, N., Ullah, A., Paramasivam, N., Öztürk, M. A., Naureen, S., *et al.* (2021) Putative second hit rare genetic variants in families with seemingly GBA-associated Parkinson's disease. *NPJ Genom. Med.* **6**, 2
 26. Frankel, R., Törnquist, M., Meisl, G., Hansson, O., Andreasson, U., Zetterberg, H., *et al.* (2019) Autocatalytic amplification of Alzheimer-associated A β 42 peptide aggregation in human cerebrospinal fluid. *Commun. Biol.* **2**, 1–11
 27. Linse, S., Scheidt, T., Bernfur, K., Vendruscolo, M., Dobson, C. M., Cohen, S. I. A., *et al.* (2020) Kinetic fingerprints differentiate the mechanisms of action of anti-A β antibodies. *Nat. Struct. Mol. Biol.* **27**, 1125–1133
 28. Kaltashov, I. A., and Abzalimov, R. R. (2011) Do ionic charges in ESI MS provide useful information on macromolecular structure? *J. Am. Soc. Mass Spectrom.* **19**, 1239–1246
 29. Konermann, L., Ahadi, E., Rodriguez, A. D., and Vahidi, S. (2013) Unraveling the mechanism of electrospray ionization. *Anal. Chem.* **85**, 2–9
 30. Biancalana, M., and Koide, S. (2010) Molecular mechanism of Thioflavin-T binding to amyloid fibrils. *Biochim. Biophys. Acta* **1804**, 1405–1412
 31. Linse, S. (2022) High-efficiency expression and purification of DNAJB6b based on the pH-modulation of solubility and denaturant-modulation of size. *Molecules* **27**, 418
 32. Munke, A., Persson, J., Weiffert, T., de Genst, E., Meisl, G., Arosio, P., *et al.* (2017) Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 6444–6449
 33. Österlund, N., Moons, R., Ilag, L. L., Sobott, F., and Graslund, A. (2019) Native ion mobility-mass spectrometry reveals the formation of β -barrel shaped amyloid- β hexamers in a membrane-mimicking environment. *J. Am. Chem. Soc.* **141**, 10440–10450
 34. Król, S., Österlund, N., Vosough, F., Jarvet, J., Wärmländer, S., Barth, A., *et al.* (2021) The amyloid-inhibiting NCAM-PrP peptide targets A β peptide aggregation in membrane-mimetic environments. *iScience* **24**, 102852
 35. Luo, J., Wärmländer, S. K., Gräslund, A., and Abrahams, J. P. (2014) Non-chaperone proteins can inhibit aggregation and cytotoxicity of Alzheimer amyloid β peptide. *J. Biol. Chem.* **289**, 27766–27775
 36. Assarsson, A., Hellstrand, E., Cabaleiro-Lago, C., and Linse, S. (2014) Charge dependent retardation of amyloid β aggregation by hydrophilic proteins. *ACS Chem. Neurosci.* **5**, 266–274
 37. Chen, G., Abelein, A., Nilsson, H. E., Leppert, A., Andrade-Talavera, Y., Tambaro, S., *et al.* (2017) Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. *Nat. Commun.* **8**, 2081
 38. Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Židek, A., *et al.* (2021) Highly accurate protein structure prediction for the human proteome. *Nature* **596**, 590–596
 39. Hipp, M. S., Park, S. H., and Hartl, U. U. (2014) Proteostasis impairment in protein-misfolding and -aggregation diseases. *Trends Cell Biol.* **24**, 506–514
 40. Pohl, C., and Dikic, I. (2019) Cellular quality control by the ubiquitin-proteasome system and autophagy. *Science* **366**, 818–822
 41. [preprint] Chou, C.-C., Vest, R., Prado, M. A., Wilson-Grady, J., Paulo, J. A., Shibuya, Y., *et al.* (2023) Proteostasis and lysosomal quality control deficits in Alzheimer's disease neurons. *bioRxiv*. <https://doi.org/10.1101/2023.03.27.534444>
 42. Mertens, J., Herdy, J. R., Traxler, L., Schafer, S. T., Schlachetzki, J. C. M., Böhnke, L., *et al.* (2021) Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer's patients. *Cell Stem Cell* **28**, 1533–1548.e6
 43. Arkan, S., Ljungberg, M., Kirik, D., and Hansen, C. (2021) DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease. *Neurobiol. Dis.* **158**, 105477
 44. Mangione, M. R., Vilasi, S., Marino, C., Librizzi, F., Canale, C., Spigolon, D., *et al.* (2016) Hsp60, amateur chaperone in amyloid-beta fibrillogenesis. *Biochim. Biophys. Acta* **1860**, 2474–2483
 45. Ghosh, S., Tugarinov, V., and Marius Clore, G. (2023) Quantitative NMR analysis of the mechanism and kinetics of chaperone Hsp104 action on amyloid- β 42 aggregation and fibril formation. *Proc. Natl. Acad. Sci. U. S. A.* **120**, e2305823120
 46. Craig, E. A. (2018) Hsp70 at the membrane: driving protein translocation. *BMC Biol.* **16**, 1–11
 47. Cohen, S. I. A., Arosio, P., Presto, J., Kurudenkandy, F. R., Biverstål, H., Dolfe, L., *et al.* (2015) A molecular chaperone breaks the catalytic cycle that generates toxic A β oligomers. *Nat. Struct. Mol. Biol.* **22**, 207–213
 48. Sinnige, T., Meisl, G., Michaels, T. C. T., Vendruscolo, M., Knowles, T. P. J., and Morimoto, R. I. (2021) Kinetic analysis reveals that independent nucleation events determine the progression of polyglutamine aggregation in *C. elegans*. *Proc. Natl. Acad. Sci. U. S. A.* **118**, e2021888118
 49. Sinnige, T. (2022) Molecular mechanisms of amyloid formation in living systems. *Chem. Sci.* **13**, 7080–7097
 50. Molenkamp, J., Den Outer, A., van Schijndel, V., and Sinnige, T. (2021) Monitoring protein aggregation kinetics in vivo using automated inclusion counting in *Caenorhabditis elegans*. *J. Vis. Exp.* **2021**, e63365
 51. Mecha, M. F., Hutchinson, R. B., Lee, J. H., and Cavagnero, S. (2022) Protein folding *in vitro* and in the cell: from a solitary journey to a team effort. *Biophys. Chem.* **287**, 106821
 52. Arosio, P., Michaels, T. C. T., Linse, S., Månsson, C., Emanuelsson, C., Presto, J., *et al.* (2016) Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation. *Nat. Commun.* **7**, 1–9
 53. Michaels, T. C. T., Šarić, A., Meisl, G., Heller, G. T., Curk, S., Arosio, P., *et al.* (2020) Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 24251–24257
 54. Nozaki, Y., and Tanford, C. (1967) Examination of titration behavior. *Methods Enzymol.* **11**, 715–734
 55. Ruiz-Sanz, J., de Prat Gay, G., Otzen, D. E., and Fersht, A. R. (1995) Protein fragments as models for events in protein folding pathways: protein engineering analysis of the association of two complementary fragments of the Barley chymotrypsin inhibitor 2 (CI-2). *Biochemistry* **34**, 1695–1701
 56. Linse, S., Thalberg, K., and Knowles, T. P. J. (2021) The unhappy chaperone. *QRB Discov.* **2**, e7
 57. Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., *et al.* (2021) Amyloid oligomers: a joint experimental/computational perspective on Alzheimer's disease, Parkinson's disease, type II diabetes, and amyotrophic lateral sclerosis. *Chem. Rev.* **121**, 2545–2647
 58. Carlsson, A., Olsson, U., and Linse, S. (2023) On the micelle behavior of DNAJB6b. *QRB Discov.* **4**, e6
 59. Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., *et al.* (2021) Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583–589
 60. [preprint] Mirdita, M., Ovchinnikov, S., and Steinegger, M. (2021) ColabFold - making protein folding accessible to all. *bioRxiv*. <https://doi.org/10.1101/2021.08.15.456425>
 61. Linse, S. (2020) Expression and purification of intrinsically disordered A β peptide and setup of reproducible aggregation kinetics experiment. *Methods Mol. Biol.* **2141**, 731–754
 62. Linse, S., Johansson, C., Brodin, P., Grundstroem, T., Drakenberg, T., and Forsen, S. (1991) Electrostatic contributions to the binding of calcium in calbindin D9k. *Biochemistry* **30**, 154–162
 63. Xue, W. F., Szczepankiewicz, O., Bauer, M. C., Thulin, E., and Linse, S. (2006) Intra- versus intermolecular interactions in monellin: contribution of surface charges to protein assembly. *J. Mol. Biol.* **358**, 1244–1255
 64. Salbo, R., Bush, M. F., Naver, H., Campuzano, I., Robinson, C. V., Pettersson, I., *et al.* (2012) Traveling-wave ion mobility mass spectrometry of protein complexes: accurate calibrated collision cross-sections of human insulin oligomers. *Rapid Commun. Mass Spectrom.* **26**, 1181–1193
 65. Drew, E. D., and Janes, R. W. (2020) PDBMD2CD: providing predicted protein circular dichroism spectra from multiple molecular dynamics-generated protein structures. *Nucleic Acids Res.* **48**, W17–W24
 66. Meisl, G., Kirkegaard, J. B., Arosio, P., Michaels, T. C. T., Vendruscolo, M., Dobson, C. M., *et al.* (2016) Molecular mechanisms of protein aggregation from global fitting of kinetic models. *Nat. Protoc.* **11**, 252–272